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Duration of SHIV production by 
infected cells is not exponentially 
distributed: Implications for 
estimates of infection parameters 
and antiviral efficacy
Catherine A. A. Beauchemin1,2, Tomoyuki Miura3 & Shingo Iwami4,5
The duration of the eclipse phase, from cell infection to the production and release of the first virion 
progeny, immediately followed by the virus-production phase, from the first to the last virion progeny, 
are important steps in a viral infection, by setting the pace of infection progression and modulating 
the response to antiviral therapy. Using a mathematical model (MM) and data for the infection of 
HSC-F cells with SHIV in vitro, we reconfirm our earlier finding that the eclipse phase duration follows 
a fat-tailed distribution, lasting 19 h (18–20 h). Most importantly, for the first time, we show that the 
virus-producing phase duration, which lasts 11 h (9.8–12 h), follows a normal-like distribution, and 
not an exponential distribution as is typically assumed. We explore the significance of this finding 
and its impact on analysis of plasma viral load decays in HIV patients under antiviral therapy. We find 
that incorrect assumptions about the eclipse and virus-producing phase distributions can lead to an 
overestimation of antiviral efficacy. Additionally, our predictions for the rate of plasma HIV decay under 
integrase inhibitor therapy offer an opportunity to confirm whether HIV production duration in vivo also 
follows a normal distribution, as demonstrated here for SHIV infections in vitro.
In this study, we sought to determine the distributions that describe the amount of time simian CD4+ T cells 
(HSC-F cells) spend in the eclipse and virus-producing phases, upon successful infection by the SHIV-KS661 
strain of the simian-human immunodeficiency virus (SHIV). The eclipse phase is defined as the time which 
elapses between the entry of the first virion which successfully infects the cell and the release of the first virion 
produced by that newly infected cell. The virus-producing phase, which the cells enter immediately upon leav-
ing the eclipse phase, is defined as the time which elapses between production of the first and last virions by an 
infected cell, often followed by apoptosis of that cell.
In previous work by our group1, we determined that the eclipse phase in this system is ~24 h in length. But 
most importantly, we determined that the time spent in the eclipse phase by SHIV-infected HSC-F cells was dis-
tributed according to a Gamma distribution with a shape parameter nE ≈ 3.5, a finding we reconfirm herein using 
a different approach. This shape parameter, which we determine herein for both the eclipse and virus-producing 
phases, is important for a number of reasons. With respect to the eclipse phase, a shape parameter of nE = 1 indi-
cates that cells spend an exponentially-distributed amount of time in the eclipse phase, whereas n 1E  (e.g., 
nE = 20) indicates they spend a normally-distributed time in that phase. An exponentially distributed eclipse 
length implies that some cells can theoretically produce virus immediately upon infection, which is not biologi-
cally possible2. On the other hand, assuming that the eclipse length is normally distributed amounts to assuming 
that all steps or successive processes involved in this phase — from successful virion entry into cells up until 
successful budding and release of the first virions — are of somewhat similar durations, and that said durations 
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are short relative to the duration of the entire eclipse phase. Under these conditions, the eclipse phase, which 
corresponds to the total duration of all these processes, will follow a normal distribution, as per the central limit 
theorem.
Interestingly, in our previous investigation1, we found that, in fact, while this distribution for the eclipse phase 
is definitely not exponential (nE ≠ 1), it is not normal either (nE  1). Instead, it lies in between (nE = 4), i.e. a dis-
tribution that does enforce a delay before initiation of virus production, unlike the exponential distribution, but 
still keeps an exponential-like distribution for longer waiting times, unlike the very symmetric normal distribu-
tion. In other words, it allows for some cells to take a much longer than average time to produce their first virion 
progeny, referred to as a fat-tailed distribution. We believe this is because one of the processes involved in early 
SHIV replication is significantly longer than others, and possibly accounts for most of the eclipse phase’s duration. 
We suspect this step to be the integration of the reverse-transcribed SHIV DNA into the host cell’s genome. In 
contrast, we have shown that a virus like influenza A which replicates its segmented, negative-strand vRNA using 
its own polymerase, i.e. following a process devoid of this particular bottleneck, has an eclipse phase duration that 
follows a normal distribution2–4.
While we reconfirm this results for the eclipse phase distribution herein, our main focus in the present work 
is on determining, for the first time, the shape parameter which describes the phase immediately following 
the eclipse phase, namely the virus-producing phase, i.e., the duration for which cells infected with SHIV will 
produce and release virion progeny before this process is shut down, possibly as cells undergo apoptosis. An 
exponentially-distributed virus-producing phase (nI = 1) would suggest that the process which leads to the termi-
nation of SHIV production in vitro is stochastic, completely independent of the time elapsed since cell infection. 
It would imply that cessation of virus production by SHIV-infected cells in vitro is not the result of accumulation 
of toxicity or exhaustion of intracellular host resources by virus replication, nor is it a virus production shut-down 
built into the virus replication cycle. It is biologically unlikely, and possibly unrealistic, that cessation of virus 
production not be the result of at least one of these processes. Yet, all mathematical models (MMs) of SHIV 
to date have invariably assumed the virus-producing phase, i.e. the duration of virus progeny production by 
SHIV-infected cells, to be exponentially distributed. Herein we show that, at least in SHIV-infected HSC-F cells 
in vitro, the duration of the virus-producing phase decisively does not follow an exponential distribution, but 
rather a normal-like distribution. We also evaluate the impact of assuming an exponentially vs a normally dis-
tributed virus-producing phase on the analysis of viral load decays observed in HIV patients treated with various 
antiviral regimens.
Results
Determining the distribution of the eclipse and virus-producing phases. Our goal is to determine 
the shape of the distributions describing the amount of time SHIV-infected cells spend in the eclipse phase, i.e. 
from successful virus entry to the release of the first virion, and then in the virus-producing phase, i.e. the dura-
tion of SHIV production from the release of the first to the last virion progeny by an infected cell. We use an 
Erlang distribution — a special case of the Gamma distribution in which the shape parameter must be an integer 
— to describe the cell-to-cell variability in the amount of time spent by SHIV-KS661 -infected cells in each of 
these two phases. By varying the value of the Erlang distribution’s shape parameter, one can shift the distribution 
from an exponential (= 1) to a normal (1) distribution, as illustrated in Fig. 1. As such, determination of the 
Figure 1. Effect of the Erlang distribution’s shape parameter. The Erlang distribution is used herein to 
describe the cell-to-cell variability in the time spent by SHIV-infected cells in the eclipse and virus-producing 
phases. As the Erlang shape parameter (nE or nI in MM (1), for the eclipse and virus-producing phases, 
respectively) is increased, the distribution of the phase duration shifts from an exponential (n = 1), to a fat-tailed 
( n [2, 10]), to a normal ( n 1), to a Dirac delta ( → ∞n ) distribution. In these graphs, the mean time spent 
by cells in the phase (τE or τI in MM (1), respectively) is fixed (set to 12 h, chosen arbitrarily) as the shape 
parameter (nE or nI) is varied. (Left) Probability density (y-axis) that a cell spend x hours in the (eclipse or 
infectious) phase. (Right) Fraction of cells (y-axis) which will remain in the phase for at least x hours.
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Erlang shape parameters for the eclipse and virus-producing phases will enable us to identify the shape of the 
distributions describing the time spent by SHIV-infected cells in these phases.
In previous work1, we used in vitro data from the infection of HSC-F cells infected with SHIV-KS661 at a 
concentration of 4.2 TCID50/cell to identify this shape parameter. Specifically, given the virus concentration in 
the inoculum, we assumed that all cells were simultaneously infected, and we used the cumulative fraction of 
cells that have entered the virus-producing phase — i.e., all cells that were either positive for the presence of the 
SHIV Nef protein or were no longer viable (have presumably died as a result of infection) — to identify this shape 
parameter for the duration of the eclipse phase. This non-dynamical approach is very attractive because the shape 
of the eclipse phase length distribution can be directly observed from this data alone, with the mathematical 
analysis providing a quantitative confirmation of what can already be seen.
Herein, we use a more indirect, dynamical approach by explicitly representing the kinetics of SHIV infection 
with MM (1), presented in the Methods section. This different approach enables us to relax the assumption that all 
cells were simultaneously infected by the initial inoculum, and allows us to also determine the distribution of the 
virus-producing phase duration, which until now has been assumed to be exponentially distributed. The exper-
imental data used in the present analysis includes that used in our previous work1, as well as additional data col-
lected as part of the previous experiment, but unused until now. Briefly, the experiment consisted in the infection of 
HSC-F cells with an inoculum containing SHIV-KS661 at concentrations of 4.2, 2.1, 1.1, 0.53, or 0.26 TCID50/cell. 
The total virus concentration (vRNA/mL), the fraction of viable HSC-F cells, and the fraction of virus-producing 
(i.e., SHIV Nef-positive cells) were determined at regular intervals over the course of the infection.
The complete experimental data set is presented in Fig. 2, alongside simulated infection time courses from MM 
(1). The two solid lines in Fig. 2 correspond to the two best-fits of MM (1) to the data when we assume that the 
duration of the virus-producing phase is distributed either exponentially (nI = 1), as is typically assumed in all exist-
ing MMs for (S)HIV, or that it is normally distributed (nI = 20, chosen based on a more thorough best-fit analysis 
described below). While both distributions visually seem to provide reasonable fit to the data, the fit which assumes 
that SHIV-infected cells produce virus over a normally distributed amount of time is better (lower sum-of-squared 
residuals or SSR of 115, computed as per Eqn. (2)) than that assuming it is exponentially distributed (SSR of 135).
To investigate this further, we used a Markov chain Monte Carlo (MCMC) approach to determine the poste-
rior likelihood distribution (PLD) for each of the MM parameters. In particular, we sought to determine the 
likelihood that the virus-producing phase is exponentially (nI = 1) versus normally ( n 1I ) distributed, given the 
set of observed experimental data. These results are presented graphically in Fig. 3, and quantitatively in Table 1. 
Figure 2. Time course of SHIV-KS661 infection of HSC-F cells and MM agreement. HSC-F cells were 
infected with SHIV-KS661 at a multiplicity of infection (MOI) or 4.2, 2.1, 1.1, 0.53, or 0.26 TCID50/cell, as 
indicated. At various times post-inoculation, the total viral load (top row), the fraction of virus-producing 
(Nef-positive) cells (middle row), and the fraction of dead cells (bottom rows) were determined as described in 
Methods. The lines correspond to the best-fits of MM (1) to this data set under the assumption that the virus-
producing phase follows an exponential (nI = 1, black line) or a normal-like (nI = 20, coloured line) distribution 
(see Methods for MM parameter values). We find that a normal-like distribution for the duration of virus 
production yields a better agreement with the data (smaller SSR) than an exponential distribution.
www.nature.com/scientificreports/
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We find that all parameters are robustly extracted (see Supplementary Fig. S1 for 2-parameter PLDs), with little 
to no correlations resulting in narrow PLDs. The MCMC analysis determined that newly infected HSC-F cells 
spent 19 h (95% credible region or CR of τE = 18–20 h) in the eclipse phase before they begin producing 
SHIV-KS661 progeny. Once underway, virus production proceeds at a rate of 5,000 (95% CR: pRNA = 4,000–6,300) 
SHIV virion per cell per day which infected cells maintain for 11 h (95% CR: τI = 9.8–12 h) before presumably 
undergoing apoptosis. This results in a total burst size of 2,500 (95% CR: pRNA · τI = 1,600–3,200) SHIV-KS661 
virion produced by each SHIV-infected HSC-F cell over its virus-producing lifespan. Despite this high virus yield, 
infection progresses slowly with 18 h (95% CR: tinf = 14–25 h) elapsed between the start of virion progeny produc-
tion and infection of the first cell by that progeny, resulting in a modest basic reproductive number of 1.7 (95% 
CR: R0 = 0.91–2.9). We also confirm our earlier finding that the duration of the eclipse phase follows a fat-tailed 
distribution that is somewhere between exponential and normal, with a shape parameter value of 4 (95% CR: 
nE = [3–5]), in agreement with the value of 3.5 obtained previously using a different approach1.
Of greatest interest, however, is the PLD of the parameter characterizing the shape of the distribution for the 
duration of the virus-production phase, nI. Because values of n 1I  are statistically equivalently likely, we con-
strained our MCMC process to values of nI ∈ [1, 100]. As such, the PLD for nI is not a true posterior likelihood 
density. Nonetheless, this enables us to identify that the mode of the PLD is 12, with a 95% CR of [6, 97]. 
Furthermore, out of the > 7,000,000 MCMC-accepted parameters, corresponding to roughly 100,000 independ-
ent parameter estimates (given our autocorrelation length of ~70), not a single one had nI = 1. Therefore, based on 
Feldman and Cousins5, we can state with 95% confidence that the likelihood of an exponentially-distributed 
virus-producing phase (nI = 1) is no more than 3 in 100,000 or < 10−4.
Figure 3. Posterior likelihood distributions of the key SHIV replication parameters. (a–j) A MCMC 
method was used to identify the posterior likelihood distributions (PLDs) for the value of MM (1)‘s parameters 
given the experimental data shown in Fig. 2. The likelihoods (y-axis of the PLDs) have been rescaled by the 
frequency of the mode. Note that the parameters corresponding to the number of eclipse (nE) and virus-
producing (nI) equations can only take on integer values. Additionally, the PLD for parameter nI in panel (j) is 
not a true PLD because nI was constrained to be ∈ [1, 100], wherein the upper-limit of 100 was chosen arbitrarily 
given that values for n 1I  are statistically equivalently likely. (k) To supplement the MCMC analysis, a best-fit 
likelihood (BFL) was obtained via a series of nonlinear fits performed while holding parameter nI fixed to values 
ranging from nI = 1 to 100. The red dots indicate the best-fits for the exponential (nI = 1) and normal-like 
(nI = 20) distributed virus-producing phase shown in Fig. 2. The BFL was rescaled so that the maximum 
likelihood equals one (see Methods).
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In Fig. 3(k), we supplement the MCMC analysis by performing a nonlinear regression to the data presented in 
Fig. 2, while holding nI fixed to values ∈ [1, 100]. Leaving parameter nI as a free parameter to be fitted was not 
appropriate given that values of n 1I  are all equivalently likely (causing the fitter to diverge) and the fact that nI 
can only take on integer values (which causes the fitter to misbehave). We find that fits for nI ∈ [9, 100] have a 
best-fit likelihood (BFL) > 85% that of the very best BFL, obtained here for nI = 20. In particular, we find the BFL 
increases monotonically from nI = 1 to nI = 20, with the BFL for nI = 1 being < 10−4 that for nI = 20. In other words, 
both the PLD and BFL for parameter nI unambiguously, statistically significantly exclude the possibility that 
SHIV-infected cells could produce virus progeny for an exponentially distributed (nI = 1) amount of time. Instead, 
the duration of the virus-producing phase is consistent with a mildly fat-tailed or more normal-like distribution.
Impact of the eclipse and virus-producing phase distributions on predicted viral load decays 
under antiviral therapy. The shape of the distribution for the time spent by cells in the eclipse and 
virus-producing phases can appear to be a theoretical concern of little relevance to our understanding of, and 
therapeutic approach to, HIV. However, the increasing prevalence of MM analyses, and the ability they confer to 
determine antiviral efficacy based solely on early viral load decays observed in treated patients, has made them an 
essential part of the toolkit used in developing, evaluating, and optimizing novel HIV therapies. All MMs must 
invariably make assumptions and simplifications which, occasionally, can lead to misinterpretations or inaccurate 
quantification. Here, we tackle one such simplification in the context of our findings regarding the shape param-
eters of the eclipse and virus-producing phase distributions.
To date, almost all MMs applied to the analysis of HIV infection kinetics have assumed that the durations of 
the eclipse phase and of virus production by HIV-infected cell are exponentially distributed. In other words, these 
MMs assume a cell that has just been infected can immediately begin producing virus, and that a cell which has 
just begun to produce and release HIV progeny is as likely to cease production and undergo apoptosis as one that 
has been producing virus for hours or even days. In the previous section, we established in vitro that the duration 
of the SHIV eclipse phase is fat-tailed distributed, and there is little reason to believe that this would not be the 
case in vivo. Though we have also established the duration of the virus-producing phase is normally distributed 
in vitro, this might not be the case in vivo where host factors and immune responses could abrogate or otherwise 
significantly affect the actual duration of virus production by HIV-infected cells. Therefore, it is important to 
understand how the decays predicted using the traditional MM (Exp,Exp), differ from those of the more bio-
logically correct MMs with a fat-tailed distributed eclipse phase and either an exponential (Fat,Exp) or normally 
(Fat,Norm) distributed eclipse phase. Herein, we explore the impact of this finding on interpretations of antiviral 
efficacy based on observed patterns of early plasma viral load decay upon therapy initiation in HIV patients.
In Fig. 4, we compare the rate of decay of plasma HIV viral loads decays under antiviral therapy with an inte-
grase inhibitors (INIs) such as raltegravir, as predicted by MMs. We explore how the MM-predicted HIV decay 
rates are impacted by four key infection kinetic parameters: the in vivo HIV clearance rate, antiviral efficacy, and 
the durations of the eclipse and virus-producing phases. We investigate how that impact in turn depends on the 
assumptions made regarding the distributions of the eclipse and virus-producing phases (Exp,Exp or Fat,Exp or 
Fat,Norm). The last row of Fig. 4 shows how, for given parameter values, the MM-predicted decay rates under 
INI therapy differ between these three assumptions. For example, the predicted total vRNA viral load under INI 
therapy differs by one to two orders of magnitude (10- to 100-fold) between the MMs with an Exp vs Normal 
virus-producing lifespan. We expect such a difference would be experimentally measurable.
The traditional (Exp,Exp) MM and the two variants considered here all predict a biphasic decay under mon-
otherapy with a INI for most parameter values, as is typically observed in INI-treated HIV patients, without the 
need to resort to assuming one short-lived and one long-lived infected cell population6. For a given eclipse phase 
duration, the traditional MM predicts a lesser rate of viral load decay under therapy. As such, the traditional 
MM would likely underestimate the true eclipse phase duration. More generally, we find that having observed 
Parameter Value [95% CR]a
Eclipse phase, τE (h) 19 [18, 20]
Virus-production (infectious) phase, τI (h) 11 [9.8, 12]
Infected lifespan, τE + τI (h) 30 [28, 31]
Prod. rate, pRNA ⋅( )vRNAcell d 103.7 [3.6, 3.8]
Infectiousness, β 
⋅( )mLTCID50 d 10−4.1 [− 4.3, − 3.9]
Base MOI ( )TCID50cell 0.41 [0.30, 0.58]
Infecting time, tinf (h) 18 [14, 25]
Basic repro. num., R0 1.7 [0.91, 2.9]
Burst size, pRNA · τI ( )vRNAcell 103.4 [3.2, 3.5]
# eclipse eqns., nE 4 [3, 5]
# virus-production eqns., nI 12 [6, 97]
Table 1.  Parameters characterizing HSC-F cell infection by SHIV-KS661. aMode of the PLD and [Bayesian 
95% credible region (CR)].
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a given decay in a patient, use of the traditional MM (Exp,Exp) to analyse said decay will overestimate the true 
antiviral efficacy and/or the HIV clearance rate, and/or it will underestimate the true duration of the eclipse or 
virus-producing phase. The over/under-estimation is even greater if one further assumes that the virus-producing 
duration is normally (Fat,Norm) rather than exponentially (Fat,Exp) distributed. For example, the decay pre-
dicted under INI therapy at 90% efficacy by the (Fat,Norm) MM (yellow line) is predicted at an antiviral efficacy 
of ~99% by the traditional (Exp,Exp) MM (blue line). The 10-fold difference (10% vs 1% antiviral escape) in the 
Figure 4. Comparison of viral load decays under integrase inhibitor therapy for different eclipse and 
virus-producing phase distributions. Using MM (3), we simulated the expected decays in plasma HIV viral 
load under therapy with an integrase inhibitor. The top three rows explore how four key in vivo viral kinetic 
parameters — rate of HIV viral clearance, antiviral efficacy, and the durations of the eclipse and virus-producing 
phases — affect the MM-predicted plasma HIV viral load decay under therapy (red to purple = lowest to 
highest parameter value), when assuming exponentially distributed eclipse and virus-producing phases 
(Exp, Exp, nE, nI = [1, 1]), or a fat-tailed distributed eclipse phase with an exponential (Fat, Exp, nE, nI = [4, 1]) or 
normally distributed (Fat, Norm, nE, nI = [4, 12]) virus-producing phase. Values of the viral clearance rate (cbody) 
of 1, 2, 3, 5, 20, and 100 h−1, of the antiviral efficacy (εIN) of 0.5, 0.7, 0.9, 0.95, 0.99, and 0.999, of the eclipse (τE) 
or virus-producing (τI) phases of 1, 6, 12, 24, 36, and 48 h are explored. The bottom row explores the effects 
of the MM choice on the expected decay of plasma HIV total and infectious virus load, and eclipse and virus-
producing cells (cbody = 23 h−1, εIN = 0.97, τE = 19 h, τI = 11 h). The simulated therapy is applied at day one and 
no pharmacokinetic delay has been added.
www.nature.com/scientificreports/
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estimates between these two different MMs would likely be statistically significant and could impact other MM 
predictions such as time to antiviral resistance emergence.
The MM which assumes a normally distributed duration of virus production (Fat,Norm) predicts a very sharp 
decay at a rate proportional to the viral clearance rate, which stops in a shoulder whose depth depends on the 
antiviral efficacy, followed by a second phase of decay whose rate depends on the duration of the eclipse phase. 
This shape is observed provided the viral clearance rate (cbody) is greater than ~5 h−1 and the duration of virus pro-
duction is less than ~11 h. While it is now believed the viral clearance rate is greater than 5 h−1, and likely as high 
as 23 h−1 7, it is not clear whether or not the duration of virus production by HIV-infected cell in vivo is indeed less 
than 11 h. If it is not, the MM (Fat,Norm) predicts the duration of virus production would affect both the first and 
second phase of viral load decay, but not the depth of the shoulder.
Discussion
Herein we have made use of a mathematical model (MM) combined with a Markov chain Monte Carlo approach 
to determine the shape of the distribution describing the time spent by SHIV-infected HSC-F cells in the eclipse 
and virus-producing phases. In previous work1, we determined that a Gamma shape parameter of 3.5 best 
describes the distribution of time spent by cells in the eclipse phase, i.e. the time elapsed between cell infection 
and the release of the first SHIV progeny by that cell. Herein, we reconfirm this finding (we found a value of 4 with 
a 95% credible region (CR) of [3–5]) using a more extensive data set and a different approach.
However, the primary aim of the present work was to extract the shape parameter for the phase which follows 
the eclipse phase, namely the virus-producing phase, i.e. the time elapsed between production of the first and 
last virus progeny by a productively SHIV-infected cell. MMs for (S)HIV infection kinetics have, up until this 
point, almost always assumed that the virus-producing phase is exponentially distributed. Herein, our exper-
imental data, MM, and analysis, enable us to statistically exclude (probability < 10−4) the hypothesis that the 
duration of virus production by SHIV-infected HSC-F cells follows an exponential distribution. Instead, we find 
that the Gamma shape parameter for the distribution of time SHIV-cells spend in the virus-producing phase is 
~12, consistent with a mildly fat-tailed or normal-like distribution (nI = [6, 97], 95% CR). To our knowledge, 
this is the first time the virus-producing lifespan of SHIV-infected cells in vitro has ever been shown to follow 
a normal-like distribution, rather than an exponential distribution as has been assumed in all MMs for (S)HIV 
until now. This finding is consistent with earlier work by Petravic et al.8 which also suggests that the eclipse 
phase duration and virus-producing lifespan of HIV-infected cells in vitro are inconsistent with an exponential 
distribution. Due to the nature of the data used in their analysis, Petravic et al. assumed, rather than identified, 
that the duration of both the eclipse and virus-production phases followed a fat-tailed, log-normal-like distribu-
tion. Such a distribution is consistent with that identified here for the duration of the eclipse phase, but differs 
from the more normal-like distribution favoured herein by our MCMC analysis for the virus-production phase. 
However, since Petravic et al. assumed rather than determined the distribution, it is likely that a normally distrib-
uted virus-production phase would also successfully reproduce their data.
Use of a normally rather than an exponentially distributed virus-producing cell lifespan can also impact 
estimates of the key SHIV kinetic parameters from MM analysis. Our results establish that SHIV-infected cells 
begin progeny virus production and release approximately 19 h (τE ∈ [18, 20] h) post-infection, and cease approx-
imately 11 h (τI ∈ [9.8, 12] h) after they have begun, or 30 h (τE + τI ∈ [28, 31] h) after the successful entry of the 
virion which infected them. This appears to be consistent with the distributions parametrised by Petravic et al.8 
for the duration of the eclipse and virus-production phases of HIV-infected cells in vitro whose mode we vis-
ually estimate to be about 28 h (τE) and 12 h (τI), respectively. In contrast, our estimates for the duration of the 
virus-producing cell lifespan (τI) obtained herein is 1.7–2.1× longer than that obtained in previous work9 wherein 
an exponentially-distributed virus-producing cell lifespan was assumed. Our estimate of the basic reproductive 
number, namely the number of secondary cells infected by the virus progeny produced by a single SHIV-infected 
cells over its virus-producing lifespan in vitro, was 1.7 (R0 ∈ [0.91, 2.9]), lower than previously estimated in vivo 
ranges of 4.3–13 assuming no eclipse phase or 5.4–54 assuming an exponential eclipse phase, both estimated in 
ref. 10, or 4–11 assuming no eclipse phase in ref. 11 for HIV-1 infections in human patients, and 2.2–4.6 assuming 
no eclipse phase in macaques infected with simian immunodeficiency virus (SIV)12.
MMs are widely used to analyse and interpret the decay of plasma HIV load in patients treated with antivirals. 
Hence, we also investigated the impact of assuming the eclipse and virus-producing phases are exponentially 
distributed, as is typically done, in analysing and interpreting said decays. Assuming the eclipse phase dura-
tion is exponentially-distributed, which is inconsistent with our findings herein, can cause an overestimation of 
the antiviral efficacy or an underestimation of the duration of the eclipse or virus-producing phases. The over/
under-estimation is even more significant if the true duration of virus-production is normally, rather than expo-
nentially distributed. Having found a 10-fold difference in the antiviral efficacy estimated by MMs with an expo-
nential vs normally distributed virus-producing cell lifespan, we expect these parameter over/under-estimation 
from viral decay data observed under INI therapy would be statistically significant. In turn, these statistically 
significant differences in parameter value estimates could potentially have an impact on therapeutic decisions. 
Actual analysis of viral load decays under therapy using these different MMs is needed to confirm this possibility, 
and to identify which parameter(s) would be most significantly affected. Previous works analysing plasma viral 
load decays under antiviral therapy in vivo, such as that by Althaus et al. for HIV13 and by Rong et al. for hepatitis 
C virus14, suggest that such MM differences can lead to statistically significantly different parameter estimates.
We furthermore find that under antiviral therapy with an integrase inhibitor (INI), the shape of the 
MM-predicted decay differs drastically between the assumption of a normally vs exponentially distributed dura-
tion of virus production. The true decays observed in HIV patients under INI therapy6 thus far can be reproduced 
under either assumptions (not shown here), albeit for different parameter values. As such, it is not currently possi-
ble to use this distinction to confirm the true duration of virus production by HIV-infected cells in vivo. However, 
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under the assumption of a normally-distributed virus-production phase, and when that phase is less than ~11 h in 
duration, the MM-predicted viral load decay is very sharp, occurring over a few hours, with a drop proportional 
to the efficacy of the INI therapy. This pattern cannot be reproduced under the assumption of an exponential 
duration of virus-production. Observing such a pattern under INI therapy would require more frequent sampling 
early after therapy initiation, and would provide a strong confirmation that the duration of virus production by 
HIV-infected cells in vivo follow a normal-like distribution.
A normally distributed duration of virus production indicates that the time of cessation of virus production 
by SHIV-infected cells in vitro occurs some relatively fixed amount of time after the start of virus production 
and release. This implies that the cause of this cessation is likely a consequence of that production and release 
process, such as the accumulation of damage (e.g., cytotoxicity, host cell resource exhaustion) or signalling (e.g., 
down-regulation due to virus replication-triggered cytokines). Recently, measuring intracellular HIV-1 replica-
tion kinetics alongside gene expression, with high temporal resolution, has become possible15. Such methodology 
would enable investigation of the detailed apoptotic gene expression profile during HIV-1 infection. This, in turn, 
would permit accurate quantification of the duration of virus progeny production and the mechanisms behind 
its cessation.
Our results are based on analysis of in vitro infection of HSC-F cells with SHIV-KS661. However, in the 
context of an in vivo HIV infection, the host immune response, absent in our in vitro analysis, might alter the 
distribution and duration of the virus-production phase. For example, killing of virus-producing cells by the host 
immune response might lead to an exponentially distributed virus-producing phase, but only if HIV-infected 
cells which have just begun virus production are killed at the same rates as those which have been producing HIV 
progeny for a while. It would furthermore require that a majority of HIV-producing cells cease virus production 
because of that host immune response so that cells exhibiting an exponentially distributed infectious lifespan 
dominates over those exhibiting their ‘natural’, normal-like duration of virus production. Viral load decay rates — 
believed to be proportional to the duration of the virus production phase — were reported to be the same in the 
presence and absence of CD8+ T cells in macaques chronically infected with SIV under combination antiretrovi-
ral therapy16–18. This suggests that at least the killing of SIV-infected cells by CD8+ T cell in vivo would not signifi-
cantly affect virus-production duration. Additionally, while the rate of host-mediated killing of HIV-infected cells 
is high in the acute phase of an HIV infection, this rate is likely much lower in the chronic phase of the disease, 
when antiviral therapy is administered and studied. Using a mathematical modelling analysis, Ganusov et al.19  
found a large decrease in the rate of viral escape from cytotoxic T lymphocyte (CTL) killing between the acute 
and chronic phases of HIV-1 infections and suggest this would be consistent with a decrease in the magnitude 
of epitope-specific CTL responses. For all these reasons, it is not inconceivable that the duration of virus pro-
duction by HIV-infected T cells in vivo also follows a normal distribution, like that characterized herein for the 
SHIV-infection of HSC-F cells in vitro.
Methods
Quantification of viable and infected cells. These experimental procedures were outlined in ref. 1, but 
are repeated here for completeness. Virus infection of the HSC-F cells was measured by FACS analysis using 
markers for surface CD4 and intracellular SIV Nef antigen expression. The number of total and viable cells were 
first determined using an automated blood cell counter (F-820; Sysmex, Kobe, Japan). Viable HSC-F cells (gated 
by forward- and side-scatter results) were examined by flow cytometry to measure the surface CD4 and intra-
cellular SIV Nef antigen expression. Cells were permeabilized with detergent-containing buffer (Permeabilizing 
Solution 2, BD Biosciences, San Jose, CA). The permeabilized cells were stained with phycoerythrin conjugated 
anti-human CD4 monoclonal antibody (Clone Nu-TH/I; Nichirei, Tokyo, Japan) and anti-SIV Nef monoclonal 
antibody (04-001, Santa Cruz Biotechnology, Santa Cruz, CA) labelled by Zenon Alexa Fluor 488 (Invitrogen, 
Carlsbad, CA), and analyzed on FACSCalibur (BD Biosciences, San Jose, CA).
Quantification of viral load. These experimental procedures were outlined in ref. 1, but are repeated here 
for completeness. The total viral load was measured via real-time PCR quantification, as described previously9,20. 
Briefly, total RNA was isolated from the 100 fold diluted culture supernatants (140 μ L) of virus-infected HSC-F 
cells with a QIAamp Viral RNA Mini kit (QIAGEN, Hilden, Germany). RT reactions and PCR were performed 
by a QuantiTect probe RT-PCR Kit (QIAGEN, Hilden, Germany) using the following primers for the gag region; 
SIV2-696F (5′ -GGA AAT TAC CCA GTA CAA CAA ATAGG-3′ ) and SIV2-784R (5′ -TCT ATC AAT TTT ACC 
CAGGCA TTT A-3′ ). A labelled probe, SIV2-731T (5′ -Fam-TGTCCA CCT GCC ATT AAG CCC G-Tamra-3′ ), 
was used for detection of the PCR products. These reactions were performed with a Prism 7500 Sequence 
Detector (Applied Biosystems, Foster City, CA) and analyzed using the manufacturer’s software. For each run, 
a standard curve was generated from dilutions whose copy numbers were known, and the RNA in the culture 
supernatant samples was quantified based on the standard curve.
Mathematical model (MM). In order to compare distributions ranging from exponential, to normal-like, 
to Dirac delta-like for the duration spent by cells in the eclipse phase (E) and in the subsequent virus-producing 
infectious phase (I), we follow previous work1–3 and adopt a set of ordinary differential equations which make use 
of an Erlang distribution to represent these phases, namely
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Herein, susceptible, target HSC-F cells are infected at rate β by infectious virus, V TCID50, and upon successful 
infection, they enter the eclipse phase, = …Ei n1, , E wherein they are SHIV-infected, but are not yet producing infec-tious virus. After an average time τE has elapsed since becoming infected, cells in the eclipse phase become infec-
tious, = …I j n1, , I, wherein they are assumed to produce infection (V TCID50) and total (VRNA) virus at a constant rates 
pTCID50 and pRNA, respectively. Ultimately, virus-producing infectious cells cease virus production, possibly under-going apoptosis, after spending an average time τI in the virus-producing state. Total virus, VRNA, quantified via 
real-time quantitative PCR in units of vRNA/mL, was measured experimentally over the course of the infection. 
Infectious virus, V TCID50, typically quantified via tissue culture infectious dose in units of TCID50/mL was not measured experimentally. The rate of cell infection is dependent on the concentration of infectious virus, not total 
virus. The ratio of infectious to total virus is not constant over the course of an in vitro SHIV infection due to the 
differing rates at which infectious virus loses infectivity compared to the rate at which total virus degrades or 
breaks down, i.e., cTCID50 for V TCID50 and cRNA for VRNA where >c cTCID RNA50 . Therefore, in MM (1), both the total and infectious virus population is accounted for: the former for comparison to experimental measurements, the 
latter to appropriately capture infection kinetics.
The time spent by newly infected cells in each of the eclipse and virus-producing phases is represented in MM 
(1) by the Erlang distribution, a special case of the Gamma distribution in which the shape parameter (here nE 
and nI) can only take on integer values. In Eqn. (1), the eclipse (or infectious) phase is separated into nE (or nI) 
separate compartments, each lasting an exponentially-distributed time of equal average length τE/nE (or τI/nI). 
As such, cells will spend on average τE (or τI) time in the eclipse (or infectious) state prior to transitioning to the 
infectious (or dead) state.
We also define the following, additional, derived parameters which are computed from the base MM param-
eters introduced above. The infecting time, which corresponds to the time elapsed between the production of the 






where N = 106 is the number of cells in the culture. The basic reproductive number, which corresponds to the 
number of secondary infections resulting from a single infected cell over its virus-producing lifespan in a fully 









Experimental and mathematically simulated in vitro SHIV infections. Experimentally, HSC-F 
cells were incubated with SHIV-KS661 and centrifuged at 4,000 rpm for 1 h at 25 °C, then rinsed three times 
as described in ref. 1. In order to computationally reproduce the experimental infection of HSC-F cells with 
SHIV-KS661, we used MM (1) with the following initial conditions. We consider the rinse time to correspond 
to t = 0 such that the infection, and therefore the mathematical simulation, begins at time t = − 1 h, followed by 
a rinse at time t = 0, after which the infection is allowed to proceed without further intervention. This is because 
each sample (time point measurements of virus or cell viability or cell infection status) are taken from separate 
wells (independent replicates) such that each time point corresponds to an infection left undisturbed since rins-
ing, up until sampling. Thus, at time t = − 1 h, we assume that no cell is initially infected (Ei = Ij = D = 0). We 
further assume that not all HSC-F cells are susceptible to SHIV infection (T(− 1 h) = 0.9 × 106), because ~10% of 
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cells appear to have remained uninfected by the end of the experiment (see Fig. 2). We found that this assumption 
(90% rather than 100% cell susceptibility to infection) was better supported (significantly better SSR) by the data.
The experimental infections were preformed at five different virus concentrations, namely at an undiluted 
infectious SHIV-KS661 concentration of 4.2 TCID50/cell (Base MOI), and at serial 2-fold dilutions down to 2.1, 
1.1, 0.53, and 0.26 TCID50/cell in four additional experiments. Mathematically, this is represented by setting the 





, where dil = 0, 1, 2, 3, 4 is the 
dilution factor of the initial inoculum which is used undiluted (dil = 0), or diluted by 2-fold in four 
additional experiments. As such, our Base MOI should correspond to an initial virus inoculum of 
4.2 × 106 TCID50/mL. However, since there is poor correspondence between virus infectiousness across separate 
experiments3, i.e. TCID50 is a relative rather than an absolute measure of virus infectiousness21,22, the true Base 
MOI was left as a free parameter to be determined. The initial total virus concentration was set to 
− = − ⋅ ×V V( 1h) ( 1h) 6 10 vRNA/TCIDRNA TCID
3
5050
 based on the ratio of 6,000 vRNA per TCID50 in our 
SHIV-KS661 samples, specifically, the ratio of the initial (t = 0) data points in Fig. 2 of Iwami et al.9.
After the 1 h incubation period, the cells are rinsed three times to remove excess virus. Based on the experi-
mental measurements presented in Fig. 2, it would appear that at high virus inocula (MOI = 4.2, and 2.1 
TCID50/cell), the residual virus post-rinse was not proportional to the inoculum, but rather seemed to reduce to 
the residual virus down to ~1.4 × 109 vRNA/mL, whereas at the lower virus inocula, the rinse did seem to result 
in residual virus proportional to the inocula. Therefore, in our MM, we simulate the rinse by multiplying both 
V (0)TCID50  and VRNA(0) at time t = 0 by . × V1 4 10 / (0)
9
RNA  which is proportional to the true rinse. Since only total 
virus is measured (VRNA), yet has no impact on our simulated infection kinetics which instead depends on infec-
tious virus ( )V TCID50 , application of a proportional rather than an absolute rinsing factor merely means that the 
units of the rates of infectious virus production pTCID50 and infectivity β will be relatively, rather than absolutely accurate, which is always the case21.
In addition to its initial conditions, MM (1) contains a total of 9 parameters: β, pTCID50, pRNA, cTCID50, cRNA, τE, 
τI, nE, and nI. From our previous work reported in Iwami et al.9, we have determined the rate of loss of infectious 
and total SHIV-KS661 virions to be = .c 0 93/dayTCID50  and = .c 0 039/dayRNA , respectively, and the rate of infec-
tious virus production to be = ⋅ . × −p p 8 63 10 TCID /vRNATCID RNA
6
5050
, which we use since infectious virus is 
not explicitly measured in the experiments analyzed herein. This leaves a total of 6 parameters (β, pRNA, τE, τI, nE, 
nI) and one initial condition (Base MOI) to be estimated by our analysis. In performing the nonlinear least-square 
fits (Figs 2 and 3), we fixed nE and nI to various integer values ∈ [1, 100], while allowing the remaining 5 quantities 
to vary. The best-fit parameters obtained for the exponential (nI = 1) and best fit for a normal-like distribution 
(nI = 20) are presented in Table 2. In constructing the Markov chain Monte Carlo (Fig. 3), we allowed all 7 quan-
tities to vary. The parameters obtained through the MCMC process are presented in Table 1.
In matching the experimental data to variables of our MMs, we compared the experimentally quantified total 
virus concentration via real-time quantitative PCR (vRNA/mL) to MM variable VRNA, compared the fraction of 
virus-producing cells tagged via anti-SIV Nef monoclonal antibodies and quantified via FACS to the sum of all 
MM variables corresponding to the fraction of cells in the infectious, virus-producing phase = ∑ =I Ij
n
j1
I , and 
compared the fraction of non-viable cells quantified using FACS gated by forward- and side-scatter to MM vari-
able D corresponding to the fraction of dead cells. In our nonlinear least-square regressions to identify the best-fit, 
6-parameter set for two different values of nI, we aimed to maximize the goodness-of-fit by minimizing the 




Eclipse phase, τE (h) 17.1 19.0
Infectious, virus-production phase, τI (h) 14.0 11.0
Infected lifespan, τE + τI (h) 31.0 30.0
Prod. rate, pRNA ⋅( )vRNAcell d 103.67 103.69
Infectiousness, β 
⋅( )mLTCID50 d 10−4.12 10−4.11
Base MOI ( )TCID50cell 0.429 0.410
Infecting time, tinf (h) 19.4 18.7
Basic repro. num., R0 1.91 1.62
Burst size, pRNA · τI ( )vRNAcell 103.44 103.35
# eclipse eqns, nE 5 4
# virus-production eqns, nI [FIXED] 1 20
Goodness of fit (SSR) 135 115
Table 2.  Best-fit parameters for exponential vs normal-like virus production phase*. *Best fits are shown in Fig. 2.
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where σ = .0 19 log (TCID /mL)V 10 50 , σI = 0.047, and σD = 0.080 correspond to the standard deviations of the 
pooled residuals for each of Vlog ( )10 RNAvidata , Iii
data and Ddi
data, respectively, for 100 best fits performed for nI ∈ [1, 100]. 
Iii and Ddi in the above correspond to fraction rather than number of cells. The SSR calculation directly uses the 
fraction of cells, and no transformation (e.g. logit function) is applied in calculating the SSR for the fractions of 
infectious or dead cells. This is because we found that the distribution of the best-fit residuals of the cell fraction data 
resembles a Gaussian while that for the residuals of the logit-transformed cell fraction data does not (not shown).
The nonlinear regression was performed using successive applications of python’s scipy implementations 
of the Levenberg-Marquardt (scipy.optimize.leastsq) and Nelder-Mead downhill simplex (scipy.optimize.
fmin) methods. Additionally, we used emcee, a python module implementation of the Markov chain Monte 
Carlo (MCMC) method23, to identify the posterior distributions for all seven MM parameters from a total of 
> 7,000,000 MCMC-accepted parameter sets. In constructing the MCMC chains, exp(− SSR/2) was used as the 
likelihood function for each set of parameters (dimensions), where the SSR is computed as per Eqn. (2). The 
‘Best-fit likelihood’ (BFL) graph which appears in Fig. 3(k) was computed as exp(− SSR/2) of the minimum SSR 
obtained via a best-fit for each individual value of nI ∈ [1, 100], divided by the likelihood of the very best fit 
(nI = 1) so that the latter’s likelihood is one.
Simulation of in vivo antiviral therapies with various modes of action. To simulate therapy with an 
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simulate only the early viral decay post therapy initiation. The new parameter = −c 23daybody
1 is the rate of clear-
ance of HIV from the plasma of chronically infected HIV patients, as previously estimated7. Because 
 c c cbody TCID RNA50 , the rates of loss of infectivity = .
−c( 0 93day )TCID
1
50
 and viral degradation 
= . −c( 0 039day )RNA
1  can be safely neglected.
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where we set τE = 19 h, τI = 11 h, nE = 1 or 4 (exponential or fat-tailed eclipse phase), and nI = 1 or 90 (exponen-
tially vs normally distributed virus-producing lifespan), based on Table  1. Additionally, we set 
=T 750,000cell/mL and = .n E 2 0cell/mLE i  based on refs 24,25. We use = .V 1 0vRNA/mLRNA  since the value of 
this variable is not important to the MM-predicted kinetics and is equivalent to rescaling the viral load to its 
starting, steady state value. As in MM (1), we set = . × ⋅−p p(8 63 10 TCID /vRNA)TCID
6
50 RNA50
. Following the 
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